Go Pro
NASDAQ:INAB

IN8bio Q4 2024 Earnings Report

IN8bio logo
$0.98 0.00 (-0.28%)
Closing price 08/10/2026 04:00 PM Eastern
Extended Trading
$0.99 +0.01 (+1.44%)
As of 07:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IN8bio EPS Results

Actual EPS
-$1.20
Consensus EPS
-$2.10
Beat/Miss
Beat by +$0.90
One Year Ago EPS
N/A

IN8bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

IN8bio Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 13, 2025
Conference Call Time
4:00PM ET

IN8bio Earnings Headlines

FY2029 Earnings Forecast for IN8bio Issued By HC Wainwright
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
See More IN8bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IN8bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IN8bio and other key companies, straight to your email.

About IN8bio

IN8bio (NASDAQ:INAB) is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications.

View IN8bio Profile